Skip to main content
Tocilizumab raises risk of diverticulitis and GI perforation vs. rituximab and abatacept in RA
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Tocilizumab raises risk of diverticulitis and GI perforation vs. rituximab and abatacept in RA
User login
Username
Password
Reset your password
Concept
Lead
score
Rheumatoid Arthritis
1
1
Diverticulitis
0
0.84
Diverticular Disease
0
0.8
Antineoplastic Drug
0
0.48
Monoclonal Antibody
0
0.48
Biologic Therapy
0
0.46
Grant
0
0.24
Arthritis
0
0.12
Specialty
Lead
score
Rheumatology
1
1
Internal Medicine
0
1
Gastroenterology
0
0.8
Hematology-Oncology
0
0.46
Pharmacist
0
0.46
Orthopaedics
0
0.18
Family Medicine/Primary Care
0
0.16
Edit Tags